On November 6, 2017, Sandoz, Inc. filed its eighth inter partes review (“IPR”) against AbbVie Biotechnology Ltd. (“AbbVie”),...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
AbbVie
-
-
On September 28, 2017, AbbVie and Amgen announced a global settlement of their patent dispute surrounding Amgen’s proposed biosimilar to...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Recently, AbbVie, Inc. and AbbVie Biotechnology, LTD (collectively “AbbVie” or “Plaintiffs”) filed a Complaint in the United States...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Boehringer Ingelheim International GMBH and Boehringer Ingelheim Pharmaceuticals, Inc. (“Boehringer Ingelheim”) have prevailed in two...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On June 22, 2017, the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicine’s Agency (“EMA”)...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Fujifilm Kyowa Kirin Biologics announced that its Medical Marketing Application (“MMA”) for FKB327, a biosimilar to AbbVie’s Humira®...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Amgen’s Amgevita, an adalimumab biosimilar to AbbVie’s Humira®, received approval from the European Commission on March 23, 2017. ...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Samsung Bioepsis UK Limited (“Samsung”), Biogen Idec Limited (“Biogen”), and Fujifilm Kyowa Kirin Biologic Company Limited...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]